Skip Navigation



JAC Advance Access published online on March 24, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh153
© 2004 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/5/743    most recent
dkh153v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Warn, P. A.
Right arrow Articles by Denning, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Warn, P. A.
Right arrow Articles by Denning, D. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 The British Society for Antimicrobial Chemotherapy

Original article

Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida

Peter A. Warn 1 *, A. Sharp 1 , J. Guinea 1 , and David W. Denning 2

1 School of Medicine, University of Manchester, Hope Hospital, Salford M6 8HD;
2 School of Medicine, University of Manchester, Hope Hospital, Salford M6 8HD; Wythenshawe Hospital, Southmoor Road, Manchester M23 9PL, UK

* Corresponding author. E-mail: pwarn{at}fs1.ho.man.ac.uk.

Received 20 March 2003 ; revised 20 January 2004 ; accepted 27 January 2004

Abstract

Objectives: The aim of this study was to investigate the effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus (four species) and Candida (six species).

Methods: In vitro susceptibility tests were set up according to NCCLS M27-A2 and M38-A recommendations, but incubation atmospheres were either air plus 5% CO2, 1% oxygen/5% CO2/94% nitrogen or 0.25% oxygen/5% CO2/94.75% nitrogen.

Results: In all Aspergillus species, the MIC of amphotericin B was reduced but the MFC remained unaltered with reduced oxygen. The MICs and MFCs of itraconazole and micafungin were unaltered in hypoxic conditions but interpretation of the MIC was much simpler for micafungin with 1% and 0.25% oxygen. Against Candida, conditions modelling hypoxia had little effect on the MICs and MFCs of any of the agents.

Conclusions: This simple adaptation of susceptibility testing may have important consequences for understanding how antifungal drugs work and for endpoint reading.

Keywords: antifungals, hypoxia, susceptibility tests
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
S. Perkhofer, D. Jost, M. P. Dierich, and C. Lass-Florl
Susceptibility Testing of Anidulafungin and Voriconazole Alone and in Combination against Conidia and Hyphae of Aspergillus spp. under Hypoxic Conditions
Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1873 - 1875.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Guinea, T. Pelaez, S. Recio, M. Torres-Narbona, and E. Bouza
In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium Species
Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1396 - 1400.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
P. A. Warn, A. Sharp, J. Mosquera, J. Spickermann, A. Schmitt-Hoffmann, M. Heep, and D. W. Denning
Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus
J. Antimicrob. Chemother., December 1, 2006; 58(6): 1198 - 1207.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. G. Dennis, W. R. Greco, Y. Brun, R. Youn, H. K. Slocum, R. J. Bernacki, R. Lewis, N. Wiederhold, S. M. Holland, R. Petraitiene, et al.
Effect of Amphotericin B and Micafungin Combination on Survival, Histopathology, and Fungal Burden in Experimental Aspergillosis in the p47phox-/- Mouse Model of Chronic Granulomatous Disease
Antimicrob. Agents Chemother., February 1, 2006; 50(2): 422 - 427.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
P. A. Warn, A. Sharp, and D. W. Denning
In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.
J. Antimicrob. Chemother., January 1, 2006; 57(1): 135 - 138.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.